OR WAIT null SECS
November 01, 2019
Published on Oct. 29, 2019, the study focuses on the multidrug-resistant bacterium Pseudomonas aeruginosa (P. aeruginosa) and how it can be used to develop new and sustainable antibiotic treatments.
The partnership will center on the development and commercialization of DCR-HBVS, Dicerna’s investigational therapy in Phase I clinical development, using its proprietary RNAi platform technology.
The project will seek to deliver treatments for the underlying cause of cystic fibrosis through submitted proposals from potential collaborators.
October 28, 2019
Principal scientist and R&D project manager at Rousselot, Jos Olijve, will discuss the details of the study at the “Influence of Endotoxin on Cellular Activity” conference on day two of CPhI Worldwide from 3:20 pm to 3:50 pm in the Portalhaus, Transparenz 1 room.
October 24, 2019
The goal of the investment is for the cures to be made available across the globe, including in sub-Saharan Africa’s low-resource communities.
The therapy received positive results in a randomized, double-blind, placebo-controlled clinical trial in 34 adults with proven celiac disease.
Under the agreement, gene and cell therapy companies can go directly to Aldevron for NTC’s technology without acquiring a license from NTC.
The company will produce the anti-HER3 antibody drug HMBD-001for use within a clinical partnership between Cancer Research UK and Hummingbird Bioscience to test the agent in a Phase I trial.
October 16, 2019
The long-term agreement gives CombiGene the authority to manufacture and commercialize the drug if it is approved after clinical studies.
October 10, 2019
MilliporeSigma will now be the first company to make acoustic technology available for cell therapy manufacturing.